Natural Killer Index From Hematopoietic Stem Cell Graft

Nantes University Hospital (NUH)

Status: Completed

Conditions: Acute Myeloblastic Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia

Treatments: Procedure: Blood test

Study type: Interventional

Funder types: Other

Identifiers

NCT00435864

BRD 06/6-N

ID RCB 2007-A00002-51

Details and patient eligibility

About

Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple donor/recipient. There is still a lot of issues non resolved: Are KIR really expressed and how occur their expression during time when hematopoietic reconstitution? Is it depending on HLA of the recipient?If KIR are expressed, what are the mechanisms of alloreactivity of NK cells? Are NK able to lyse tumoral cells? Could alloreactive NK cells constitute a therapeutic tool able to induce tolerance and elimination of leukemia during hematopoietic stem cells grafts?

Enrollment: 92 patients

Sex: All

Ages: 1+ year old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age superior to 1 year
• Patient that will be treated by an HSC graft
• Initial pathology of recipient: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myeloid leukemia

Exclusion criteria

• Patient already included in a study with an exclusion period
• HIV + or HCV + serology during pre-graft analysis
• Patient already treated by an allograft of HSC

Trial design

Primary purpose: Health Services Research

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

92 participants in 3 patient groups

allogeneic donor from a file

Other group

Treatment:

Procedure: Blood test

Registry geno-identical donor family

Other group

Treatment:

Procedure: Blood test

transplantation of HSCs derived from placental blood

Other group

Treatment:

Procedure: Blood test